Effect of prostaglandins and aspirin on active E-rosette formation in patients with multiple sclerosis

Halina Offner; Bente Danneskiold-Samsøe; Paula Dore-Duffy

doi:10.1016/0090-1229(82)90034-4

Effect of prostaglandins and aspirin on active E-rosette formation in patients with multiple sclerosis

Halina Offner, Bente Danneskiold-Samsøe, Paula Dore-Duffy

Research output: Contribution to journal › Article

8 Scopus citations

Abstract

Active E-rosette-forming lymphocytes were examined in patients with multiple sclerosis, patients with other neurological diseases, and patients with rheumatoid arthritis. Significantly fewer (P <0.01) active E rosettes were found in multiple sclerosis and RA patients than in controls. The lower levels of active E rosettes in MS could be enhanced by physiological levels of prostaglandins E₁ and E₂ (10^-4 and 10^-11 M). MS patients appar to have a circulating population of immature E-rosetting lymphocytes sensitive to modulation with prostaglandin E.

Original language	English (US)
Pages (from-to)	159-167
Number of pages	9
Journal	Clinical Immunology and Immunopathology
Volume	22
Issue number	2
DOIs	https://doi.org/10.1016/0090-1229(82)90034-4
Publication status	Published - 1982
Externally published	Yes

Fingerprint

ASJC Scopus subject areas

Immunology
Immunology and Allergy
Pathology and Forensic Medicine

Cite this

Offner, H., Danneskiold-Samsøe, B., & Dore-Duffy, P. (1982). Effect of prostaglandins and aspirin on active E-rosette formation in patients with multiple sclerosis. Clinical Immunology and Immunopathology, 22(2), 159-167. https://doi.org/10.1016/0090-1229(82)90034-4

@article{72f5b70822654aa7bff36e6dfd196ce5,

title = "Effect of prostaglandins and aspirin on active E-rosette formation in patients with multiple sclerosis",

abstract = "Active E-rosette-forming lymphocytes were examined in patients with multiple sclerosis, patients with other neurological diseases, and patients with rheumatoid arthritis. Significantly fewer (P <0.01) active E rosettes were found in multiple sclerosis and RA patients than in controls. The lower levels of active E rosettes in MS could be enhanced by physiological levels of prostaglandins E1 and E2 (10-4 and 10-11 M). MS patients appar to have a circulating population of immature E-rosetting lymphocytes sensitive to modulation with prostaglandin E.",

author = "Halina Offner and Bente Danneskiold-Sams{\o}e and Paula Dore-Duffy",

year = "1982",

doi = "10.1016/0090-1229(82)90034-4",

language = "English (US)",

volume = "22",

pages = "159--167",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Effect of prostaglandins and aspirin on active E-rosette formation in patients with multiple sclerosis

AU - Offner, Halina

AU - Danneskiold-Samsøe, Bente

AU - Dore-Duffy, Paula

PY - 1982

Y1 - 1982

N2 - Active E-rosette-forming lymphocytes were examined in patients with multiple sclerosis, patients with other neurological diseases, and patients with rheumatoid arthritis. Significantly fewer (P <0.01) active E rosettes were found in multiple sclerosis and RA patients than in controls. The lower levels of active E rosettes in MS could be enhanced by physiological levels of prostaglandins E1 and E2 (10-4 and 10-11 M). MS patients appar to have a circulating population of immature E-rosetting lymphocytes sensitive to modulation with prostaglandin E.

AB - Active E-rosette-forming lymphocytes were examined in patients with multiple sclerosis, patients with other neurological diseases, and patients with rheumatoid arthritis. Significantly fewer (P <0.01) active E rosettes were found in multiple sclerosis and RA patients than in controls. The lower levels of active E rosettes in MS could be enhanced by physiological levels of prostaglandins E1 and E2 (10-4 and 10-11 M). MS patients appar to have a circulating population of immature E-rosetting lymphocytes sensitive to modulation with prostaglandin E.

UR - http://www.scopus.com/inward/record.url?scp=0020082448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020082448&partnerID=8YFLogxK

U2 - 10.1016/0090-1229(82)90034-4

DO - 10.1016/0090-1229(82)90034-4

M3 - Article

C2 - 6286189

AN - SCOPUS:0020082448

VL - 22

SP - 159

EP - 167

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -

Access to Document

10.1016/0090-1229(82)90034-4